Completed

Assessment of Mast Cell Activation Diagnostic Test in Patients With Allergic Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
No DNA Sample
Who is being recruted

Chronic Urticaria+16

+ Mast Cell Activation Syndrome

+ Mast Cell Activation Disorders

Over 18 Years
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: February 2018
See protocol details

Summary

Principal SponsorHong Kong Sanatorium & Hospital
Last updated: January 18, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2018

Actual date on which the first participant was enrolled.

The objective of this study is to assess whether patients with severe allergic diseases exhibit high levels of mast cell activation as determined by the mast cell activation diagnostic test the investigators have developed. They anticipate that patients with history of severe allergic reactions will show up as high responders in the blood-based mast cell activation diagnostic test. Moreover, using microarray analysis as the approach for gene expression studies, they anticipate further that genomics biomarkers that are correlated with the high functional activation of the in-vitro mast cells derived from these patients can be readily identified. About 100 ml of peripheral venous blood from individual patients will be drawn into heparinized syringes and collected in a blood-collecting bag/tube containing silica. The bag/tube will be promptly processed for the generation of primary human mast cell cultures using the protocol that has previously been developed \[Inflammation Research 66: 25 (2017). After culturing for 9 weeks, the resulting human mast cells will be analyzed for both their functional activity in terms of histamine release in response to the activation of high-affinity Immunoglobulin E (IgE) receptors in these cells and their gene expression profiles using microarray analysis. The in-vitro functional and genomics data will be correlated with specific diagnoses and measurements of blood prostaglandin D2 (PGD2), PGD2 metabolites, tryptase and histamine levels in blood. For mediator assays, plasma from each subject will be collected after the cluster of differentiation 34 positive (CD34+) isolation step and the samples will be aliquoted and frozen at -80 degrees centigrade for subsequent analysis.

Official TitleAssessment of Mast Cell Activation Diagnostic Test in Patients With Allergic Disease 
NCT03406325
Principal SponsorHong Kong Sanatorium & Hospital
Last updated: January 18, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

19 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic UrticariaMast Cell Activation SyndromeMast Cell Activation DisordersAnaphylaxisChronic DiseaseFood HypersensitivityHypersensitivityHypersensitivity, ImmediateImmune System DiseasesMastocytosisNeoplasmsNeoplasms by Histologic TypeNeoplasms, Connective TissuePathologic ProcessesSkin DiseasesUrticariaSkin Diseases, VascularNeoplasms, Connective and Soft TissueDisease Attributes

Criteria

Inclusion Criteria: Any patients with the above diagnoses - Exclusion Criteria: Children \< 18 years old; those who are unwilling or unable to donate blood; pregnant mothers. -

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Hong Kong Sanatorium & Hospital

Hong Kong, Hong KongSee the location
CompletedOne Study Center